Cardiovascular disease risk in rheumatoid arthritis anno 2022
B Dijkshoorn, R Raadsen, MT Nurmohamed - Journal of clinical medicine, 2022 - mdpi.com
The risk for developing cardiovascular diseases (CVD) in rheumatoid arthritis (RA) patients
is 1.5 times higher compared to the general population. This risk is partly due to the …
is 1.5 times higher compared to the general population. This risk is partly due to the …
Managing cardiovascular and cancer risk associated with JAK inhibitors
Janus kinase inhibitors (JAKi) have enormous appeal as immune-modulating therapies
across many chronic inflammatory diseases, but recently this promise has been …
across many chronic inflammatory diseases, but recently this promise has been …
Safety of Janus kinase inhibitors: a real-world multicenter retrospective cohort study
M Lanzillotta, N Boffini, E Barone, G Cincinelli… - The Journal of …, 2023 - jrheum.org
Objective Oral Janus kinase inhibitors (JAKis) represent an effective strategy for rheumatoid
arthritis (RA) treatment. A previous study supported that tofacitinib (TOF) is associated with …
arthritis (RA) treatment. A previous study supported that tofacitinib (TOF) is associated with …
Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box
Considerable controversy related to the cardiovascular safety of Janus kinase inhibitors
(JAKinibs) has arisen following the results of the ORAL Surveillance trial. In this trial of …
(JAKinibs) has arisen following the results of the ORAL Surveillance trial. In this trial of …
Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review
M Mansilla-Polo, D Morgado-Carrasco - Dermatology and Therapy, 2024 - Springer
Introduction Biological drugs (BD) and Janus kinase inhibitors (JAKi) have revolutionized
the treatment of diverse dermatoses. However, there are concerns regarding their safety …
the treatment of diverse dermatoses. However, there are concerns regarding their safety …
How to Use Janus Kinase Inhibitors in the Treatment of Rheumatoid Arthritis? A Clinical Assessment of Risks and Benefits
FK Alduraibi, JA Singh - Current Rheumatology Reports, 2023 - Springer
Abstract Purpose of Review To provide an updated understanding of risks and benefits of
Janus kinase inhibitors (JAKi) versus biologic disease-modifying antirheumatic drugs …
Janus kinase inhibitors (JAKi) versus biologic disease-modifying antirheumatic drugs …
[PDF][PDF] TOFACITINIB: CURRENT CONSIDERATIONS IN THE MANAGEMENT OF IMMUNE INFLAMMATORY DISORDERS
A Erden - Rheumatology Quarterly, 2023 - researchgate.net
Tofacitinib, the first member of targeted-synthetic disease-modifying antirheumatic drugs, is
an oral inhibitor of Janus kinases (JAKs), preferentially JAK-1 and 3. It is an analog of …
an oral inhibitor of Janus kinases (JAKs), preferentially JAK-1 and 3. It is an analog of …